SCHEMBL26328530

SCHEMBL26328530

CC(C)(C)Cc1cccc(NC(C)(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 1/20 0.38
ESR1 P03372 1/20 0.36
GRIN2D O15399 2/20 0.36
GRIN3B O60391 2/20 0.36
GRIN1 Q05586 2/20 0.36
GRIN2A Q12879 2/20 0.36
GRIN2B Q13224 2/20 0.36
GRIN2C Q14957 2/20 0.36
GRIN3A Q8TCU5 2/20 0.36
SIGMAR1 Q99720 2/20 0.36
PDK1 Q15118 1/20 0.36
PDK2 Q15119 1/20 0.36
PDK3 Q15120 1/20 0.36
PDK4 Q16654 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.34
CYP2D6 P10635 1/20 0.34
MAPT P10636 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
IKBKB O14920 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13884327 0.84 RAPGEF4 (0.40) RAPGEF4GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL16236758 0.84 RAPGEF4 (0.51) RAPGEF4GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL10026816 0.82 LMNA (0.39) RAPGEF4ESR1GRIN2DGRIN3BGRIN1
SCHEMBL10294036 0.81 PDK1 (0.53) RAPGEF4GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL27112966 0.81 HTR6 (0.46) RAPGEF4GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL23332106 0.79 MAPT (0.54) RAPGEF4ALDH1A1LMNACYP2D6MAPT
SCHEMBL13884318 0.79 ALDH1A1 (0.42) ALDH1A1LMNACYP2D6MAPTSMN1; SMN2
SCHEMBL20319309 0.79 LMNA (0.42) ALDH1A1LMNACYP2D6MAPTHDAC11
SCHEMBL15034736 0.78 ALDH1A1 (0.45) ALDH1A1LMNAHPGD
SCHEMBL20782198 0.78 ADRA2A (0.52) LMNAMAPTIKBKBPTPRBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 US disclosed
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation C4 THERAPEUTICS, INC. (US) 2023-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION STUB1, MDM2, USP30 RAPGEF4 3850/4885ESR1 1132/4885GRIN2D 4807/4885
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation CRBN, CBL, STUB1 RAPGEF4 3813/4885ESR1 1237/4885GRIN2D 4702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.